<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="by the novel coronavirus SARS-CoV-2, which first emerged in Wuhan," exact="China" post="and was made known to the World in December"/>
 <result pre="Generally well tolerated, increased ALT/AST [42] Danoprevir ChEMBL2311191 Approved in" exact="China" post="2018 Ascletis by Roche - Faldaprevir ChEMBL1241348 Phase III"/>
 <result pre="Johnson &amp;amp; Johnson Rash, anemia, leukopenia/neutropenia [44] Vaniprevir ChEMBL599872 Approved" exact="Japan" post="2014 Merck &amp;amp; Co. Diarrhea, nausea [45] DPP-4 inhibitors"/>
 <result pre="Increased risk of heart failure [46] Anagliptin - Approved in" exact="Japan" post="2012 Sanwa Kagaku Kenkyusho - Dutogliptin - Phase III"/>
 <result pre="LG Life Sciences Generally well tolerated Gosogliptin - Approved in" exact="Russia" post="2016 Pfizer Hypoglycemia [48] Linagliptin ChEMBL237500 Approved 2011 Eli"/>
 <result pre="and Merck KGaA Not known yet Omarigliptin ChEMBL2105762 Approved in" exact="Japan" post="2012 Merck &amp;amp; Co. Generally well tolerated Saxagliptin ChEMBL385517"/>
 <result pre="legs, upper respiratory tract infection [51] Teneligliptin - Approved in" exact="Japan" post="2012 Mitsubishi Tanabe Pharma Generally well tolerated Trelagliptin -"/>
 <result pre="Mitsubishi Tanabe Pharma Generally well tolerated Trelagliptin - Approved in" exact="Japan" post="2015 Takeda Generally well tolerated Vildagliptin ChEMBL142703 Approved 2007"/>
</results>
